Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
UNLABELLED: This study assessed the effects of the serotonin (5-HT) and norepinephrine (NE) transporter inhibitor duloxetine on the effects of 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy) in vitro and in 16 healthy subjects. The clinical study used a double-blind, randomized, placebo-controlled, four-session, crossover design. In vitro, duloxetine blocked the release of both 5-HT and NE by MDMA or by its metabolite 3,4-methylenedioxyamphetamine from transmitter-loaded human cells expressing the 5-HT or NE transporter. In humans, duloxetine inhibited the effects of MDMA including elevations in circulating NE, increases in blood pressure and heart rate, and the subjective drug effects. Duloxetine inhibited the pharmacodynamic response to MDMA despite an increase in duloxetine-associated elevations in plasma MDMA levels. The findings confirm the important role of MDMA-induced 5-HT and NE release in the psychotropic effects of MDMA. Duloxetine may be useful in the treatment of psychostimulant dependence. TRIAL REGISTRATION: Clinicaltrials.gov NCT00990067.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
The SCL-90 and the MMPI: A Step in the Validation of a New Self-Report Scale
Derogatis, L. R., Rickels, K., & Rock, A. F. (1976) · British Journal of Psychiatry · doi:10.1192/bjp.128.3.280 · Cited by 2,298 · cited 2×
“25 kg/m(2), (iv) personal or family (first-degree relative) history of psychiatric disorder (determined by the structured clinical interview of Axis I and Axis II disorders according the Diagnostic and Statistical Manual of Mental Disorders, 4 edition [18] supplemented by the SCL-90-R Symptom Checklist [19,20] (v) reg…”
BackgroundInfluentialPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Psychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683 · cited 2×
“The psychometric measures included Visual Analog Scales (VAS) [8,10], the Adjective Mood Rating Scale (AMRS) [21], and 5-Dimensions of Altered States of Consciousness (5D-ASC) [22,23].”
BackgroundMethodThe Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans
Dittrich, A. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979351 · Cited by 577
The Symptom Check-List-90-R (SCL-90-R): A German validation study
Schmitz, N., Hartkamp, N., Kiuse, J., Franke, G. H., Reister, G., & Tress, W. (2000) · Quality of Life Research · doi:10.1023/a:1008931926181 · Cited by 430 · cited 2×
“25 kg/m(2), (iv) personal or family (first-degree relative) history of psychiatric disorder (determined by the structured clinical interview of Axis I and Axis II disorders according the Diagnostic and Statistical Manual of Mental Disorders, 4 edition [18] supplemented by the SCL-90-R Symptom Checklist [19,20] (v) reg…”
BackgroundInfluentialLiechti, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00148-7 · Cited by 248 · cited 1×
“. In humans, SERT inhibition reduced the psychotropic response to MDMA”
BackgroundSelf-citationBedi, G., Hyman, D., & de Wit, H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.003 · Cited by 247
Camí, J., Farré, M., Mas, M., Roset, P. N., Poudevida, S., Mas, A., San, L., & de la Torre, R. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200008000-00010 · Cited by 234 · cited 1×
“The VASs included ‘‘any drug effect,’’ ‘‘good drug effect,’’ ‘‘bad drug effect,’’ ‘‘drug liking,’’ ‘‘drug high,’’ ‘‘stimulated,’’ ‘‘fear,’’ ‘‘closeness to others,’’ ‘‘talkative,’’ and ‘‘open’’ [8,10,12,24,25].”
Wall, S. C., Gu, H., & Rudnick, G. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08574-8 · Cited by 183
Gould, G. G., Javors, M. A., & Frazer, A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.029 · Cited by 18
Cited by
Pharmacological characterization of designer cathinones in vitro
Simmler, L., Buser, T., Donzelli, M., Schramm, Y., Dieu, L., Huwyler, J., Chaboz, S., Hoener, M., & Liechti, M. (2013) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02145.x · Cited by 672
Self-citationAcute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 411
Self-citationReceptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379
Self-citationMDMA enhances emotional empathy and prosocial behavior
Hysek, C. M., Schmid, Y., Simmler, L. D., Domes, G., Heinrichs, M., Eisenegger, C., Preller, K. H., Quednow, B. B., & Liechti, M. E. (2014) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nst161 · Cited by 356
Self-citationDistinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0569-3 · Cited by 247
Self-citation
Metadata
- Authors
- Hysek, C. M., Simmler, L. D., Nicola, V. G., Vischer, N., Donzelli, M., Krähenbühl, S., Grouzmann, E., Huwyler, J., Hoener, M. C., & Liechti, M. E.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-05-04
- Volume
- 7
- Issue
- 5
- Pages
- e36476
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2089306255
- Cited by
- 157
- References
- 11
- FWCI
- 14.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.